- Home
- SLDB vs GBLI Comparison
SLDB vs GBLI Comparison
Compare SLDB & GBLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLDB
- GBLI
- Stock Information
- Founded
- SLDB 2013
- GBLI 2016
- Country
- SLDB United States
- GBLI United States
- Employees
- SLDB N/A
- GBLI N/A
- Industry
- SLDB Biotechnology: Biological Products (No Diagnostic Substances)
- GBLI Property-Casualty Insurers
- Sector
- SLDB Health Care
- GBLI Finance
- Exchange
- SLDB Nasdaq
- GBLI Nasdaq
- Market Cap
- SLDB 464.1M
- GBLI 428.9M
- IPO Year
- SLDB 2018
- GBLI 2003
- Fundamental
- Price
- SLDB $5.49
- GBLI $29.01
- Analyst Decision
- SLDB Strong Buy
- GBLI
- Analyst Count
- SLDB 10
- GBLI 0
- Target Price
- SLDB $15.00
- GBLI N/A
- AVG Volume (30 Days)
- SLDB 1.0M
- GBLI 2.3K
- Earning Date
- SLDB 11-07-2025
- GBLI 10-30-2025
- Dividend Yield
- SLDB N/A
- GBLI 4.90%
- EPS Growth
- SLDB N/A
- GBLI N/A
- EPS
- SLDB N/A
- GBLI 1.98
- Revenue
- SLDB N/A
- GBLI $439,280,000.00
- Revenue This Year
- SLDB N/A
- GBLI $5.48
- Revenue Next Year
- SLDB N/A
- GBLI $7.91
- P/E Ratio
- SLDB N/A
- GBLI $14.41
- Revenue Growth
- SLDB N/A
- GBLI N/A
- 52 Week Low
- SLDB $2.41
- GBLI $26.94
- 52 Week High
- SLDB $7.37
- GBLI $37.00
- Technical
- Relative Strength Index (RSI)
- SLDB 48.24
- GBLI 40.40
- Support Level
- SLDB $5.48
- GBLI $28.55
- Resistance Level
- SLDB $6.09
- GBLI $29.06
- Average True Range (ATR)
- SLDB 0.37
- GBLI 0.38
- MACD
- SLDB -0.03
- GBLI -0.02
- Stochastic Oscillator
- SLDB 28.26
- GBLI 1.57
About SLDB Solid Biosciences Inc.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.
About GBLI Global Indemnity Group LLC (DE)
Global Indemnity Group LLC provides both admitted and non-admitted specialty property and casualty insurance coverages and individual policyholder coverages in the United States, as well as reinsurance world-wide. The company's two segments are: Penn-America and Non-Core Operations. The Penn-America segment offers specialty property and casualty products designed for its Wholesale Commercial, Specialty Products, InsurTech, and Assumed Reinsurance product offerings. These product lines are offered in the excess and surplus lines marketplace; and Non-Core Operations segment contains lines of business that have been de-emphasized or are no longer being written. The majority of its revenue is from the the Penn-America segment . Geographically, the majority is from California.